http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100822519-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2006-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100822519-B1 |
| titleOfInvention | Single Matrix Tablets Controlled in the Gastrointestinal tract |
| abstract | The present invention,n n n a) at least one pharmacologically active substance;n n n b) a hydrogel forming material, comprising at least one component selected from poloxamer and colloidal silica and a polyethylene oxide; Andn n n c) carbon dioxide generating materialsn n n It relates to a single matrix tablet composition for gastrointestinal controlled release. The composition of the present invention may be suspended in gastric fluid to release the active substance in the gastrointestinal tract continuously at a uniform rate for at least 2 hours.n n n n Zero-order release, gastric retention, controlled release, single matrix purification |
| priorityDate | 2005-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 542.